So should Third Harmonic Bio (NASDAQ:THRD) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as ...

Third Harmonic Bio will halt non-THB335 research and cut 50% of its workforce while reviewing strategic options. Every week, our Whisper Index uncovers five overlooked stocks with big breakout ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Morgan Stanley downgraded Third Harmonic Bio (THRD) to Equal Weight from Overweight with a price target of $5, down from $20, after the company announced that it plans to evaluate strategic ...

On Tuesday, Third Harmonic Bio, Inc. (NASDAQ:THRD) revealed results from its Phase 1 single and multiple ascending dose (SAD/MAD) trial of THB335 in healthy volunteers. The company says the data ...